PT - JOURNAL ARTICLE AU - Samantha J. Mascuch AU - Sara Fakhretaha-Aval AU - Jessica C. Bowman AU - Minh Thu H. Ma AU - Gwendell Thomas AU - Bettina Bommarius AU - Chieri Ito AU - Liangjun Zhao AU - Gary P. Newnam AU - Kavita R. Matange AU - Hem R. Thapa AU - Brett Barlow AU - Rebecca K. Donegan AU - Nguyet A. Nguyen AU - Emily G. Saccuzzo AU - Chiamaka T. Obianyor AU - Suneesh C. Karunakaran AU - Pamela Pollet AU - Brooke Rothschild-Mancinelli AU - Santi Mestre-Fos AU - Rebecca Guth-Metzler AU - Anton V. Bryksin AU - Anton S. Petrov AU - Mallory Hazell AU - Carolyn B. Ibberson AU - Petar I. Penev AU - Robert G. Mannino AU - Wilbur A. Lam AU - Andrés J. Garcia AU - Julia M. Kubanek AU - Vinayak Agarwal AU - Nicholas V. Hud AU - Jennifer B. Glass AU - Loren Dean Williams AU - Raquel L. Lieberman TI - A blueprint for academic labs to produce SARS-CoV-2 RT-qPCR test kits AID - 10.1101/2020.07.29.20163949 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.29.20163949 4099 - http://medrxiv.org/content/early/2020/09/01/2020.07.29.20163949.short 4100 - http://medrxiv.org/content/early/2020/09/01/2020.07.29.20163949.full AB - Widespread testing for the presence of the novel coronavirus SARS-CoV-2 in individuals remains vital for controlling the COVID-19 pandemic prior to the advent of an effective treatment. Challenges in testing can be traced to an initial shortage of supplies, expertise and/or instrumentation necessary to detect the virus by quantitative reverse transcription polymerase chain reaction (RT-qPCR), the most robust, sensitive, and specific assay currently available. Here we show that academic biochemistry and molecular biology laboratories equipped with appropriate expertise and infrastructure can replicate commercially available SARS-CoV-2 RT-qPCR test kits and backfill pipeline shortages. The Georgia Tech COVID-19 Test Kit Support Group, composed of faculty, staff, and trainees across the biotechnology quad at Georgia Institute of Technology, synthesized multiplexed primers and probes and formulated a master mix composed of enzymes and proteins produced in-house. Our in-house kit compares favorably to a commercial product used for diagnostic testing. We also developed an environmental testing protocol to readily monitor surfaces across various campus laboratories for the presence of SARS-CoV-2. Our blueprint should be readily reproducible by research teams at other institutions, and our protocols may be modified and adapted to enable SARS-CoV-2 detection in more resource-limited settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMajor funding was provided by the State of Georgia COVID19 Testing Task Force Method Development and Supply Chain Stabilization Studies Proposal (COVID-19 Tech Support Group) and Georgia Institute of Technology. This work was also supported by NASA grants 80NSSC18K1139 and 80NSSC19K0477. RGM and WAM were supported by NIH U54EB027690.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesProtocols available on request